KalVista Pharmaceuticals, Inc. (FRA:4XC1)

Market Cap	679.17M +44.6%
Revenue (ttm)	1.25M
Net Income	-177.55M
EPS	-3.45
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	15
Open	13.30
Previous Close	12.80
Day's Range	13.30 - 13.30
52-Week Range	9.00 - 14.50
Beta	n/a
RSI	55.62
Earnings Date	Mar 10, 2026

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use ...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Benjamin Palleiko
• Employees: 270
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4XC1

Financial Performance

Financial numbers in USD